

INFORMAZIONI PERSONALI



Prof. Luca Richeldi

📍 ~~051 309361 (051 309361)~~

☎ ~~051 309361 (051 309361)~~

✉ ~~l.richeldi@uniroma2.it (l.richeldi@uniroma2.it)~~

Codice Fiscale: ~~051 309361 (051 309361)~~

Data di Nascita ~~051 309361 (051 309361)~~

Luogo di Nascita ~~Modena (Modena)~~

Nazionalità: Italiana

Iscrizione Albo dei Medici e Chirurghi di Modena: n. 4225 del 14/01/1989

ATTUALE POSIZIONE RICOPERTA

Luca Richeldi ricopre la carica di **Professore delle Malattie dell'Apparato Respiratorio** presso la Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore di Roma (dal gennaio 2017 ad oggi).

Direttore dell'Unità Operativa Complessa di Pneumologia presso il Dipartimento di Scienze Mediche e Chirurgiche presso la Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore di Roma (dal gennaio 2017 ad oggi).

Dal 14 ottobre 2018 ricopre la carica di **Presidente della Società Italiana di Pneumologia (SIP/IRS)**

Dal 1° dicembre 2020 ricopre la carica di **Presidente della Fleischner Society** (2020-2021)

ESPERIENZA PROFESSIONALE

Dal 2013 al 2016

Direttore del Centro per le Malattie Rare del Polmone e Professore Associato di malattie dell'apparato respiratorio presso l'Università di Southampton (Inghilterra) - Consulente Onorario presso il "General Hospital MHS Trust" di Southampton (Inghilterra) - Vice Direttore della Facoltà di Medicina.

Dal 2005 al 2013

Professore Associato di Medicina Respiratoria presso l'Università di Modena e Reggio Emilia (Italia).

Dal 2005 al 2008

Direttore della Scuola di Specializzazione di Medicina Respiratoria presso l'Università di Modena (Italia).

Dal 2006 al 2013

Consulente Onorario di malattie dell'Apparato Respiratorio presso l'AOU Policlinico di Modena (Italia)

Dal 2007 al 2013

Direttore del Centro per le Malattia Rare del Polmone presso l'AOU Policlinico di Modena (Italia).

Da 1997 al 2005

Consulente in Medicina Respiratoria presso il Policlinico di Modena (Italia).

Dal 1996 al 1997

Professore a contratto presso la Scuola di Specializzazione in Malattie dell'Apparato Respiratorio presso l'Università di Roma "La Sapienza" (Italia).

Dal 1993 al 1996

Dottorato di Ricerca in Fisiopatologia Cardiorespiratoria presso l'Università di Roma "La Sapienza" (Italia).

Dal 1990 al 1993

Dottorato di Ricerca presso l'Università di Roma "La Sapienza" (Italia)

Anno 1988

Laurea in Medicina presso l'Università di Modena (Italia) e nello stesso anno consegue l'abilitazione alla professione di Medico Chirurgo.

Il Prof. Luca Richeldi è Responsabile della stesura delle linee guida Internazionali sulla **Diagnosi e Terapia della Fibrosi Polmonare Idiopatica** (*Idiopathic Pulmonary Fibrosis*) e sulla classificazione della polmonite interstiziale idiopatica – linee guida e raccomandazioni approvate dalle più prestigiose società internazionali in campo Respiratorio tra cui "American Thoracic Society" e la "European Respiratory Society".

MEMBRO DEI COMITATI INTERNAZIONALI

- American Thoracic Society, "Microbiology, Tuberculosis and Pulmonary Infections": membro della Conference Program Committee (2006-2009), del Planning Committee (2009-2011) e del Nominating Committee (2012-2013)
- Centers for Disease Control and Prevention, USA, Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection: membro del comitato scientifico (2009-2010).
- American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Respiratory Society, Evidence-based Guidelines for Management of Idiopathic Pulmonary Fibrosis: membro del comitato scientifico (2007-2011)
- American Thoracic Society/European Respiratory Society, International Multidisciplinary

Classification of Idiopathic Interstitial Pneumonias: membro del Comitato scientifico (dal 2009 ad oggi)

- American Thoracic Society/European Respiratory Society, International Working Group on Undifferentiated forms of CTD-ILD: membro del Comitato scientifico (dal 2012 ad oggi)
- American Thoracic Society, "Clinical problems assembly": membro della Conference Program Committee (2014-2016)

MEMBRO DELLE SOCIETA' INTERNAZIONALI SCIENTIFICHE

- Pulmonary Fibrosis Foundation: Presidente del Gruppo Internazionale
- The Association of Physicians of Great Britain and Ireland: membro
- The Cochrane Collaboration: membro (Gruppo "Airways")
- American Thoracic Society: membro
- European Respiratory Society: membro
- Italian Respiratory Society: membro e segretario del gruppo "Infections and Tuberculosis"

PUBBLICAZIONI DI RICERCA SCIENTIFICA (articoli, capitoli, case report, review, editoriali)

Total citations: 20.473

H-index: 58

Luca Richeldi ha contribuito alla stesura di vari capitoli medico-scientifici ed è autore di più di 280 articoli scientifici pubblicati nei giornali internazionali tra cui:

1. Capelli A, Capelli O, Azzolini L, **Richeldi L**, Prandi E, Velluti G. Activities of human alveolar macrophages (HAMs). Note 1: Observations on phagocytosis and bacterial killing in the presence of miocamycin. *Chemioterapia*. 1988; 7(2): 89-95.
2. Velluti G, Capelli O, **Richeldi L**, Prandi E, Lega M, Rovatti E, Covi M. Functional activities of human alveolar macrophages. *Eur Respir J*. 1990; 3(3): 361-2.
3. Saltini C, **Richeldi L**, Holroyd KJ, du Bois RM, Crystal RG. Lymphocytes. *The Lung: Scientific Foundations*. Crystal RG and West JB editors. Raven Press, New York, N.Y. 1991, 459-82
4. Saltini C, Amicosante M, Li Bianchi E, Paone G, **Richeldi L**, Guerritore D, Pallotta G, Bisetti A. [Mycobacterium tuberculosis. From the gene to the diagnosis]. *Recenti Prog Med*. 1992; 83(1): 38-45.
5. Amicosante M, Paone G, Ameglio F, Bianchi EL, Piccolella E, **Richeldi L**, Bisetti A, Luisetti M, Saltini C. Antibody repertoire against the A60 antigen complex during the course of pulmonary tuberculosis. *Eur Respir J*. 1993; 6(6): 816-22.
6. **Richeldi L**, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. *Science*. 1993; 262(5131): 242-4.
7. Saltini C, Sorrentino R, **Richeldi L**, Luisetti M, Bisetti A. Role of the HLA-DP gene in susceptibility to lung granulomas. *Sarcoidosis*. 1993; 10(2): 171-2.

8. Saltini C, **Richeldi L**. A genetic marker for chronic beryllium disease. Workshop on the practical applications of biomarkers in medicine. The development and applications of biomarkers Ed. U.S. Department of Energy, Washington D.C., April 15, 1994, 51.
9. **Richeldi L**, Barnini S, Saltini C. Molecular diagnosis of tuberculosis. *Eur Respir J Suppl.* 1995; 20: 689s-700s.
10. Saltini C, **Richeldi L**. A genetic marker for chronic beryllium disease. *Med Lav.* 1995; 86(3): 226-8.
11. Amicosante M, **Richeldi L**, Trenti G, Paone G, Campa M, Bisetti A, Saltini C. Inactivation of polymerase inhibitors for Mycobacterium tuberculosis DNA amplification in sputum by using capture resin. *J Clin Microbiol.* 1995; 33(3): 629-30.
12. Amicosante M, **Richeldi L**, Monno L, Cuboni A, Tartoni PL, Angarano G, Orefici G, Saltini C. Serological markers predicting tuberculosis in human immunodeficiency virus-infected patients. *Int J Tuberc Lung Dis.* 1997; 1(5): 435-40.
13. **Richeldi L**, Franchi A, Rovatti E, Cossarizza A, du Bois RM, Saltini C. Lymphocytes. *The Lung: Scientific Foundations.* 2nd edition. Crystal RG, West JB, Weibel ER, Barnes PJ editors. Raven Press, New York, N.Y. 1997, 187-99.
14. Rovatti E, Franchi A, **Richeldi L**, Saltini C. Lymphokines and the lung. *The Lung: Scientific Foundations.* 2nd edition. Crystal RG, West JB, Weibel ER, Barnes PJ editors. Raven Press, New York, N.Y. 1997, 803-20.
15. **Richeldi L**, Kreiss K, Mroz MM, Zhen B, Tartoni P, Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. *Am J Ind Med.* 1997; 32(4): 337-40.
16. Robinson DS, **Richeldi L**, Saltini C, du Bois RM. Granulomatous processes. *The Lung: Scientific Foundations.* 2nd edition. Crystal RG, West JB, Weibel ER, Barnes PJ editors. Raven Press, New York, N.Y. 1997, 2395-409.
17. Saltini C, Amicosante M, Franchi A, Lombardi G, **Richeldi L**. Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. *Eur Respir J.* 1998; 12(6): 1463-75.
18. Voorter C, **Richeldi L**, Gervais T, van den Berg-Loonen E. Identification of two new DPB1 alleles, DPB1*7701 and *7801, by sequence-based typing. *Tissue Antigens.* 1998; 52(2): 190-2.
19. Saltini C, **Richeldi L**, Amicosante M. HLA and respiratory disease. HLA in health and disease. Lechler R and Warrens A editors. Academic Press, London 2000, 263-77.
20. Agostini C, Albera C, Bariffi F, De Palma M, Harari S, Lusuardi M, Pesci A, Poletti V, **Richeldi L**, Rizzato G, Rossi A, Schiavina M, Semenzato G, Tinelli C. First report of the Italian register for diffuse infiltrative lung disorders (RIPID). *Monaldi Arch Chest Dis.* 2001; 56(4): 364-8.
21. Saltini C, **Richeldi L**, Losi M, Amicosante M, Voorter C, van den Berg-Loonen E, Dweik RA, Wiedemann HP, Deubner DC, Tinelli C. Major histocompatibility locus genetic markers of beryllium sensitization and disease. *Eur Respir J.* 2001; 18(4): 677-84.
22. Maestrelli P, **Richeldi L**, Moretti M, Fabbri LM. Analysis of sputum in COPD. *Thorax.* 2001; 56(6): 420-2.
23. Davies HR, **Richeldi L**. Idiopathic pulmonary fibrosis: current and future treatment options. *Am J Respir Med.* 2002; 1(3): 211-24.
24. Romagnoli M, **Richeldi L**, Fabbri LM. Diagnosis. Asthma and COPD. Basic mechanisms and clinical management. Barnes PJ, Drazen JM, Rennard S, Thomason NC editors. Academic Press, London 2002, 447-55.

25. **Richeldi L**, Covi M, Ferrara G, Franco F, Vailati P, Meschiari E, Fabbri LM, Velluti G. Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. *Monaldi Arch Chest Dis.* 2002; 57(1): 39-43.
26. **Richeldi L**, Ferrara G, Fabbri LM, Gibson PG. Macrolides for chronic asthma. *Cochrane Database Syst Rev.* 2002; (1): CD002997.
27. **Richeldi L**, Rossi G, Ruggieri MP, Corbetta L, Fabbri LM. Churg-Strauss syndrome in a case of asthma. *Allergy.* 2002; 57(7): 647-8.
28. Rossi G, Cavazza A, Valli R, Torricelli P, **Richeldi L**, Rivasi F, Brambilla E. Atypical lipomatous tumour (lipoma-like well-differentiated liposarcoma) arising in a pulmonary hamartoma and clinically presenting with pneumothorax. *Lung Cancer.* 2003; 39(1): 103-6.
29. Davies HR, **Richeldi L**, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. *Cochrane Database Syst Rev.* 2003; (3): CD003134.
30. Fabbri LM, Romagnoli M, **Richeldi L**, Olivieri D. Asthma versus chronic obstructive pulmonary disease. *Eur Respir Mon.* 2003; 23: 195-210.
31. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, Troiano L, **Richeldi L**, Mussini C, Esposito R, Cossarizza A. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. *AIDS.* 2003; 17(11): 1696-8.
32. **Richeldi L**, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. *Cochrane Database Syst Rev.* 2003; (3): CD002880.
33. **Richeldi L**, Ewer K, Losi M, Bergamini BM, Roversi P, Deeks J, Fabbri LM, Lalvani A. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. *Am J Respir Crit Care Med.* 2004; 170(3): 288-95.
34. **Richeldi L**, Ewer K, Losi M, Hansell DM, Roversi P, Fabbri LM, Lalvani A. Early diagnosis of subclinical multidrug-resistant tuberculosis. *Ann Intern Med.* 2004; 140(9): 709-13.
35. **Richeldi L**, Mariani M, Losi M, Maselli F, Corbetta L, Buonsanti C, Colonna M, Sinigaglia F, Panina-Bordignon P, Fabbri LM. Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections. *Eur Respir J.* 2004; 24(2): 247-50.
36. Luppi F, Cerri S, Beghe B, Fabbri LM, **Richeldi L**. Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. *Respir Med.* 2004; 98(11): 1035-44.
37. **Richeldi L**. Interferon gamma-1b for pulmonary fibrosis. *N Engl J Med.* 2004; 350(17): 1794-7; author reply -7.
38. Lalvani A, **Richeldi L**, Kunst H. Interferon gamma assays for tuberculosis. *Lancet Infect Dis.* 2005; 5(6): 322-4; author reply 5-7.
39. Ferrara G, Losi M, Franco F, Corbetta L, Fabbri LM, **Richeldi L**. Macrolides in the treatment of asthma and cystic fibrosis. *Respir Med.* 2005; 99(1): 1-10.
40. Luppi F, Cerri S, **Richeldi L**. Steroid and/or other immunosuppressive therapies in idiopathic interstitial pneumonias: have they still a role? *Sarcoidosis Vasc Diffuse Lung Dis.* 2005; 22 Suppl 1: S74-84.
41. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, Bergamini BM, D'Amico R, Marchegiano P, Rumpianesi F, Fabbri LM, **Richeldi L**. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. *Am J Respir Crit Care Med.* 2005; 172(5): 631-5.

42. Ferrara G, **Richeldi L**, Bugiani M, Cirillo D, Besozzi G, Nutini S, Casali L, Fiorentini F, Codecasa LR, Migliori GB. Management of multidrug-resistant tuberculosis in Italy. *Int J Tuberc Lung Dis.* 2005; 9(5): 507-13.
43. **Richeldi L**, De Guglielmo M, Fabbri LM, Giovanardi D, Marchetti F, Larosa M, Solfrini V, Altini M. Management of CAP using a validated risk score. *Thorax.* 2005; 60(2): 172-3.
44. **Richeldi L**, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG. Macrolides for chronic asthma. *Cochrane Database Syst Rev.* 2005; (4): CD002997.
45. Tinelli C, De Silvestri A, **Richeldi L**, Oggioni T. The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. *Sarcoidosis Vasc Diffuse Lung Dis.* 2005; 22 Suppl 1: S4-8.
46. **Richeldi L**. Chronic beryllium disease: a model for pulmonary sarcoidosis? *Acta Biomed.* 2005; 76 Suppl 2: 11-4.
47. Ferrara G, Losi M, Roversi P, Fabbri LM, **Richeldi L**. [New tools for a better diagnosis of latent tuberculosis infection]. *Recenti Prog Med.* 2006; 97(3): 123-8.
48. **Richeldi L**. An update on the diagnosis of tuberculosis infection. *Am J Respir Crit Care Med.* 2006; 174(7): 736-42.
49. Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, Mussini C, Rumpianesi F, Fabbri LM, **Richeldi L**. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with *Mycobacterium tuberculosis*: a prospective study. *Lancet [Fast Track]*. 2006; 367(9519): 1328-34.
50. **Richeldi L**, Ewer K, Losi M, Roversi P, Fabbri LM, Lalvani A. Repeated tuberculin testing does not induce false positive ELISPOT results. *Thorax.* 2006; 61(2): 180.
51. **Richeldi L**, Luppi M, Losi M, Luppi F, Potenza L, Roversi P, Cerri S, Millington KA, Ewer K, Fabbri LM, Torelli G, Lalvani A. Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. *Leukemia.* 2006; 20(2): 379-81.
52. Ciaschetti A, Franchi A, **Richeldi L**, Rumpianesi F, Meacci M, Valente A, Franco G. [Screening of latent tuberculosis infection in health care workers by QuantiFERON-TB and tuberculin skin test]. *G Ital Med Lav Ergon.* 2007; 29(3 Suppl): 406-7.
53. Davies G, Cerri S, **Richeldi L**. Rifabutin for treating pulmonary tuberculosis. *Cochrane Database Syst Rev.* 2007; (4): CD005159.
54. Franchi A, **Richeldi L**, Parrinello G, Franco G. Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patient. *Int Arch Occup Environ Health.* 2007; 80(6): 533-8.
55. Gooding S, Chowdhury O, Hinks T, **Richeldi L**, Losi M, Ewer K, Millington K, Gunatheesan R, Cerri S, McNally J, Lalvani A. Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice. *J Infect.* 2007; 54(3): e169-74.
56. Losi M, Bossink A, Codecasa L, Jafari C, Ernst M, Thijsen S, Cirillo D, Ferrarese M, Greinert U, Fabbri LM, **Richeldi L**, Lange C. Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. *Eur Respir J.* 2007; 30(6): 1173-9.
57. **Richeldi L**, Ewer K, Losi M, Bergamini BM, Millington K, Fabbri LM, Lalvani A. T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. *Pediatrics.* 2007; 119(1): e1-5.
58. **Richeldi L**, Abraham E. Identifying patients with idiopathic pulmonary fibrosis: quality or quantity? *Am J Respir Crit Care Med.* 2007; 175(10): 976-7.

59. **Richeldi L**, Losi M, Cerri S, Casali L, Fabbri LM, Ferrara G. Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay. *Expert Rev Respir Med*. 2008; 2(2): 253-60.
60. Spagnolo P, **Richeldi L**, du Bois RM. Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. *Semin Respir Crit Care Med*. 2008; 29(6): 610-9.
61. Ferrara G, Bleck B, **Richeldi L**, Reibman J, Fabbri LM, Rom WN, Condos R. Mycobacterium tuberculosis induces CCL18 expression in human macrophages. *Scand J Immunol*. 2008; 68(6): 668-74.
62. **Richeldi L**, Bergamini BM, Vaienti F. Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts. *Eur Respir J*. 2008; 32(2): 524-5.
63. Rossi G, Andreani A, Morandi P, Marchioni A, Corradini P, Cappiello G, Bortolotti M, Qosja A, Manzini C, Ferri C, **Richeldi L**, Cavazza A. Eosinophilic globules in bronchoalveolar lavage fluid of patients with systemic sclerosis-related interstitial lung disease: a diagnostically useful, previously unreported finding in a retrospective and prospective study, including differential diagnosis with other idiopathic and secondary interstitial lung diseases. *Am J Clin Pathol*. 2008; 130(6): 927-33.
64. Bergamini BM, Losi M, Vaienti F, D'Amico R, Meccugni B, Meacci M, De Giovanni D, Rumpianesi F, Fabbri LM, Balli F, **Richeldi L**. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. *Pediatrics*. 2009; 123(3): e419-24.
65. Selman M, Spagnolo P, **Richeldi L**. Interstitial lung disease in elderly subjects. *Eur Respir Mon*. 2009; 43: 150-62.
66. Spagnolo P, **Richeldi L**, Raghu G. The role of bronchoalveolar lavage cellular analysis in the diagnosis of interstitial lung diseases. *Eur Respir Mon*. 2009; 46: 36-46.
67. Spagnolo P, Luppi F, Rossi G, **Richeldi L**. To BAL or not to BAL: is this a problem in diagnosing IPF? *Am J Respir Crit Care Med*. 2009; 180(4): 379-80; author reply 80.
68. Ferrara G, Losi M, D'Amico R, Cagarelli R, Pezzi AM, Meacci M, Meccugni B, Marchetti Dori I, Rumpianesi F, Roversi P, Casali L, Fabbri LM, **Richeldi L**. Interferon-gamma-release assays detect recent tuberculosis re-infection in elderly contacts. *Int J Immunopathol Pharmacol*. 2009; 22(3): 669-77.
69. Jafari C, Thijsen S, Sotgiu G, Goletti D, Dominguez Benitez JA, Losi M, Eberhardt R, Kirsten D, Kalsdorf B, Bossink A, Latorre I, Migliori GB, Strassburg A, Winteroll S, Greinert U, **Richeldi L**, Ernst M, Lange C. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. *Am J Respir Crit Care Med*. 2009; 180(7): 666-73.
70. Du Bois RM, **Richeldi L** editors Interstitial Lung Diseases. *Eur Respir Mon*. 2009, issue 46.
71. Luppi F, Losi M, D'Amico R, Fabbri LM, **Richeldi L**. Endogenous blood maximal interferon-gamma production may predict response to interferon-gamma 1beta treatment in patients with idiopathic pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis*. 2009; 26(1): 64-8.
72. **Richeldi L**, Losi M, D'Amico R, Luppi M, Ferrari A, Mussini C, Codeluppi M, Cocchi S, Prati F, Paci V, Meacci M, Meccugni B, Rumpianesi F, Roversi P, Cerri S, Luppi F, Ferrara G, Latorre I, Gerunda GE, Torelli G, Esposito R, Fabbri LM. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. *Chest*. 2009; 136(1): 198-204.
73. Ferrara G, Losi M, Fabbri LM, Migliori GB, **Richeldi L**, Casali L. Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. *Arch Immunol Ther Exp (Warsz)*. 2009; 57(6): 425-33.

74. **Richeldi L.** Diagnosing latent tuberculosis infection: guess who's coming to dinner? *Am J Respir Crit Care Med.* 2009; 180(1): 1-2.
75. Andreani A, Cavazza A, Marchioni A, **Richeldi L**, Paci M, Rossi G. Bronchopulmonary actinomycosis associated with hiatal hernia. *Mayo Clin Proc.* 2009; 84(2): 123-8.
76. Canali E, Sola P, **Richeldi L**, Spagnolo P, Mora G, Georgouloupoulou E, Bernabei C, Malaguti MC, Valzania F, Mandrioli J. Amyotrophic lateral sclerosis and sarcoidosis: a difficult differential diagnosis. *Amyotroph Lateral Scler.* 2010; 11(4): 410-1.
77. Garlassi E, Rossi G, Bedini A, **Richeldi L.** Unexpected identification of bilateral masses in an asymptomatic heavy smoker. *Thorax.* 2010; 65(9): 846.
78. Luppi F, Beghé B, **Richeldi L.** Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed? *Am J Respir Crit Care Med.* 2010; 181(2): 102-3.
79. **Richeldi L.** [Role of in vitro tests in the diagnosis of latent tubercular infections]. *G Ital Med Lav Ergon.* 2010; 32(3): 269-72.
80. Rossi G, Tironi A, Dore R, Nannini N, Mengoli MC, Bertolani M, **Richeldi L.** Pulmonary eosinophilic infiltrates. *Pathologica.* 2010; 102(6): 537-46.
81. Spagnolo P, Zeuzem S, **Richeldi L**, du Bois RM. The complex interrelationships between chronic lung and liver disease: a review. *J Viral Hepat.* 2010; 17(6): 381-90.
82. Colaci M, Sebastiani M, Giuggioli D, Manfredi A, Spagnolo P, Luppi F, **Richeldi L**, Ferri C. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. *Scand J Rheumatol.* 2010; 39(2): 155-9.
83. Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, **Richeldi L.** Non-steroid agents for idiopathic pulmonary fibrosis. *Cochrane Database Syst Rev.* 2010; (9): CD003134.
84. Losi M, Bergamini BM, Venturelli C, Del Giovane C, Sighinolfi G, Rumpianesi F, **Richeldi L.** Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing. *Int J Tuberc Lung Dis.* 2011; 15(9): 1182-4.
85. Cerri S, Spagnolo P, Luppi F, **Richeldi L.** Smoking-related interstitial lung disease. *Eur Respir Mon.* 2011; 54: 282-300.
86. Losi M, Bocchino M, Matarese A, Bellofiore B, Roversi P, Rumpianesi F, Alma MG, Chiaradonna P, Del Giovane C, Altieri AM, **Richeldi L**, Sanduzzi A. Role of the QuantiFERON-TB test in ruling out pleural tuberculosis: a multi-centre study. *Int J Immunopathol Pharmacol.* 2011; 24(1): 159-65.
87. Luppi F, Covi M, Velluti G, Spagnolo P, Fabbri LM, **Richeldi L.** Co-trimoxazole effect on human alveolar macrophages of AIDS patients. *J Biol Regul Homeost Agents.* 2011; 25(3): 461-4.
88. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Jr., Kondoh Y, Myers J, Muller NL, Nicholson AG, **Richeldi L**, Selman M, Dudden RF, Griss BS, Protzko SL, Schönemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* 2011; 183(6): 788-824.
89. **Richeldi L**, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Klüglic M, du Bois RM. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *N Engl J Med.* 2011; 365(12): 1079-87.

90. Ruhwald M, Dominguez J, Latorre I, Losi M, **Richeldi L**, Pasticci MB, Mazzolla R, Goletti D, Butera O, Bruchfeld J, Gaines H, Gerogianni I, Tuuminen T, Ferrara G, Eugen-Olsen J, Ravn P. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with *M. tuberculosis*. *Tuberculosis (Edinb)*. 2011; 91(3): 260-7.
91. Contini P, Schiavina M, Schiavina R, Tavalazzi F, Fabiani A, Di Scioscio V, Spagnolo P, **Richeldi L**. Efficacy of hormonal suppression in a patient with chyluria due to lymphangiomyomatosis. *Multidiscip Respir Med*. 2011; 6(5): 313-7.
92. Kolb MR, **Richeldi L**. Viruses and acute exacerbations of idiopathic pulmonary fibrosis: rest in peace? *Am J Respir Crit Care Med*. 2011; 183(12): 1583-4.
93. Noble PW, **Richeldi L**, Kaminski N. End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2011; 184(1): 4-5.
94. **Richeldi L**, du Bois RM. Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. *Expert Rev Respir Med*. 2011; 5(4): 473-81.
95. Ferrara G, Parida SK, Zumla A, **Richeldi L**, Maeurer M. A decade of interferon-gamma release assays: quest for the holy grail to diagnose latent infection with *Mycobacterium tuberculosis*? *Am J Respir Crit Care Med*. 2011; 183(12): 1732.
96. **Richeldi L**, Yasothan U, Kirkpatrick P. Pirfenidone. *Nat Rev Drug Discov*. 2011; 10(7): 489-90.
97. Selman M, Pardo A, **Richeldi L**, Cerri S. Emerging drugs for idiopathic pulmonary fibrosis. *Expert Opin Emerg Drugs*. 2011; 16(2): 341-62.
98. Blasi F, Bocchino M, Di Marco F, **Richeldi L**, Aliberti S. The role of biomarkers in low respiratory tract infections. *Eur J Intern Med*. 2012; 23(5): 429-35.
99. King TE, Jr., Collard HR, **Richeldi L**. Interstitial lung diseases. Preface. *Clin Chest Med*. 2012; 33(1): xiii.
100. Cerri S, Spagnolo P, Luppi F, **Richeldi L**. Management of idiopathic pulmonary fibrosis. *Clin Chest Med*. 2012; 33(1): 85-94.
101. du Bois RM, Nathan SD, **Richeldi L**, Schwarz MI, Noble PW. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. *Am J Respir Crit Care Med*. 2012; 186(8): 712-5.
102. Luppi F, Spagnolo P, Cerri S, **Richeldi L**. The big clinical trials in idiopathic pulmonary fibrosis. *Curr Opin Pulm Med*. 2012; 18(5): 428-32.
103. **Richeldi L**. Treating idiopathic pulmonary fibrosis: current opportunities and future challenges. *Clin Respir J*. 2012; 6(3): 129-30.
104. **Richeldi L**. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. *Eur Respir Rev*. 2012; 21(124): 147-51.
105. Spagnolo P, Luppi F, Cerri S, **Richeldi L**. Genetic testing in diffuse parenchymal lung disease. *Orphanet J Rare Dis*. 2012; 7: 79.
106. Spagnolo P, Luppi F, Roversi P, Cerri S, Fabbri LM, **Richeldi L**. Sarcoidosis: challenging diagnostic aspects of an old disease. *Am J Med*. 2012; 125(2): 118-25.
107. Spagnolo P, Tonelli R, Cocconcelli E, Stefani A, **Richeldi L**. Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. *Multidiscip Respir Med*. 2012; 7(1): 42.
108. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, **Richeldi L**. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. *Thorax*. 2012; 67(11): 938-40.

109. **Richeldi L**, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Jr., Ryu JH, Collard HR. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. *Thorax*. 2012; 67(5): 407-11.
110. Ryerson CJ, Urbania TH, **Richeldi L**, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE, Jr., Wolters PJ, Collard HR. Prevalence and prognosis of unclassifiable interstitial lung disease. *Eur Respir J*. 2013; 42(3): 750-7.
111. Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, **Richeldi L**, Jones KD, King TE, Jr., Collard HR. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. *Respir Med*. 2013; 107(2): 249-55.
112. Bargellini A, Marchesi I, Marchegiano P, **Richeldi L**, Cagarelli R, Ferranti G, Borella P. A culture-proven case of community-acquired legionella pneumonia apparently classified as nosocomial: diagnostic and public health implications. *Case Rep Med*. 2013; 2013: 303712.
113. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, **Richeldi L**, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG. Treatment of idiopathic pulmonary fibrosis with ambrisentan, a selective antagonist of the endothelin a receptor: a randomized trial. *Ann Intern Med*. 2013; 158(9): 641-9.
114. Collard HR, Yow E, **Richeldi L**, Anstrom KJ, Glazer C; IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. *Respir Res*. 2013; 14: 73.
115. Travis WD, Costabel U, Hansell DM, King, Jr. TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Robalo Cordeiro C, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, **Richeldi L**, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med*. 2013; 188(6): 733-48.
116. Colaci M, Giuggioli D, Sebastiani M, Manfredi A, Vacchi C, Spagnolo P, Cerri S, Luppi F, **Richeldi L**, Ferri C. Lung cancer in scleroderma: Results from an Italian rheumatologic center and review of the literature. *Autoimmun Rev*. 2013; 12(3): 374-9.
117. **Richeldi L**, Collard HR, du Bois RM, Jenkins G, Kolb M, Maher TM, Raghu G, Vancheri C, Laurent GJ. Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis. *Eur Respir J*. 2013; 42(1): 230-8.
118. **Richeldi L**. Idiopathic pulmonary fibrosis: current challenges and future perspectives. *Eur Respir Rev*. 2013; 22(128): 103-5.
119. Costabel U, Albera C, Behr J, Cottin V, Guenther A, **Richeldi L**. Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics. *Respir Res*. 2013; 14 Suppl 1: S1.
120. **Richeldi L**. Clinical trials of investigational agents for IPF: a review of a Cochrane report. *Respir Res*. 2013; 14 Suppl 1: S4.
121. Behr J, **Richeldi L**. Recommendations on treatment for IPF. *Respir Res*. 2013; 14 Suppl 1: S6.
122. Jones MG, Fletcher S, **Richeldi L**. Idiopathic pulmonary fibrosis: recent trials and current drug therapy. *Respiration*. 2013; 86(5): 353-63.
123. Spagnolo P, Luppi F, **Richeldi L**. The reply. *Am J Med*. 2013; 126(1): e19.

124. **Richeldi L.** Treatments for idiopathic pulmonary fibrosis. *N Engl J Med.* 2014; 371: 783.
125. Cottin V, **Richeldi L.** Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. *Eur Respir Rev.* 2014; 23: 106-10.
126. Jones MG, **Richeldi L.** Air pollution and acute exacerbations of idiopathic pulmonary fibrosis: back to miasma? *Eur Respir J.* 2014; 43: 956-9.
127. Fischer A, **Richeldi L.** Cross-disciplinary collaboration in connective tissue disease-related lung disease. *Semin Respir Crit Care Med.* 2014; 35(2): 159-65.
128. Cottin V, **Richeldi L.** Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. *Eur Respir Rev.* 2014; 23: 106-10.
129. Jones MG, **Richeldi L.** Air pollution and acute exacerbations of idiopathic pulmonary fibrosis: back to miasma? *Eur Respir J.* 2014; 43: 956-9.
130. Ryerson CJ, Corte TJ, Collard HR, **Richeldi L.** A global registry for idiopathic pulmonary fibrosis: the time is now. *Eur Respir J.* 2014; 44: 273-6.
131. Wuyts WA, Antoniou KM, Borensztajn K, Costabel U, Cottin V, Crestani B, Grutters JC, Maher TM, Poletti V, **Richeldi L,** Vancheri C, Wells AU. Combination therapy: the future of management for idiopathic pulmonary fibrosis? *Lancet Respir Med.* 2014; 2: 933-42.
132. Spagnolo P, Luppi F, Montanari G, **Richeldi L.** Pharmacological Treatment of Idiopathic Pulmonary Fibrosis. *Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide.* Meyer KC and Nathan S editors. Springer 2014, volume 9, pages 297-311.
133. Moodley Y, Corte T, **Richeldi L,** King TE Jr. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. *Respirology* 2015; 20(3): 389-94.
134. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, Lesage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, **Richeldi L,** Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax.* 2014; 69: 428-36.
135. Jaffar J, Unger S, Corte TJ, Keller M, Wolters PJ, **Richeldi L,** Cerri S, Prêle CM, Hansbro PM, Argraves WS, Oliver RA, Oliver BG, Black JL, Burgess JK. Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis. *Chest* 2014 Oct;146(4):1055-1063.
136. **Richeldi L,** Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F, Stowasser S, Collard HR. Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. *Respir Med.* 2014; 108: 1023-30.
137. **Richeldi L,** du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med.* 2014; 370: 2071-82.
138. Banville N, Burgess JK, Jaffar J, Tjin G, **Richeldi L,** Cerri S, Persiani E, Black JL, Oliver BG. A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM). *PLoS One.* 2014; 9.

139. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, **Richeldi L**, King TE Jr, Collard HR. Idiopathic Pulmonary Fibrosis: CT and Risk of Death. *Radiology*. 2014; 273: 570-9.
140. Udwadia ZF, Mullerpattan JB, Balakrishnan C, **Richeldi L**. Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. *Lung India*. 2015 Jan-Feb; 32(1): 50-2.
141. Sgalla G, Cerri S, Ferrari R, Ricchieri MP, Poletti S, Ori M, Garuti M, Montanari G, Luppi F, Petropulacos K, **Richeldi L**. Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. *BMJ Open Respir Res*. 2015; 2.
142. Hansell DM, Goldin JG, King TE Jr, Lynch DA, **Richeldi L**, Wells AU. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner society. *Lancet Respir Med*. 2015; 3: 483-496.
143. Cottin V, Cordier JF and **Richeldi L** editors. Orphan lung diseases: a clinical guide to rare lung disease. Springer Verlag 2015.
144. Fischer A, Antoniou KM, Brown KK, Cadranet J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, **Richeldi L**, Streck ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V; "ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD". An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. *Eur Respir J*. 2015; 46: 976-87.
145. Raghu G, Rochweg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, **Richeldi L**, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ; ATS, ERS, JRS, and ALAT. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2015 Jul 15;192(2).
146. Thabut G, Crestani B, Porcher R, **Richeldi L**. Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough. *Eur Respir J*. 2015; 46: 607-14.
147. Costabel U, Inoue Y, **Richeldi L**, Collard HR, Tschöepe I, Stowasser S, Azuma A. Efficacy of nintedanib in idiopathic pulmonary fibrosis across pre-specified subgroups in INPULSIS. *Am J Respir Crit Care Med* 2016 Jan 15;193(2):178-85.
148. Corte T, Bonella F, Crestani B, Demedts MG, **Richeldi L**, Coeck C, Pelling K, Quaresma M, Lasky JA. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. *Respir Res*. 2015 Sep 24;16(1).
149. De Biasi S, Cerri S, Bianchini E, Gibellini L, Persiani E, Montanari G, Luppi F, Carbonelli CM, Zucchi L, Bocchino M, Zamparelli AS, Vancheri C, Sgalla G, **Richeldi L**, Cossarizza A. Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. *BMC Med*. 2015; 13: 277.
150. Spagnolo P, Maher TM, **Richeldi L**. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. *Pharmacol Ther*. 2015; 152: 18-27.
151. Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE Jr, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, **Richeldi L**, Rose D, Wells AU, Brown KK. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. *Eur Respir J*. 2015; 46: 243-9.
152. **Richeldi L**. Efficacy endpoints for idiopathic pulmonary fibrosis trials. *Lancet Respir Med*. 2015; 3: 335-7.

153. Mazzei ME, **Richeldi L**, Collard HR. Nintedanib in the treatment of idiopathic pulmonary fibrosis. *Ther Adv Respir Dis.* 2015; 9: 121-129.
154. **Richeldi L**, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. *BMC Med.* 2015 Sep 24;13(1):237.
155. **Richeldi L**. Idiopathic pulmonary fibrosis: moving forward. *BMC Med.* 2015 Sep 24;13(1):231.
156. **Richeldi L**. Time for Prevention of Idiopathic Pulmonary Fibrosis Exacerbation. *Ann Am Thorac Soc.* 2015; 12 Suppl 2: S181-5.
157. **Richeldi L**, Le Maulf F, Schlenker-Herceg R, Collard HR. Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials? *Am J Respir Crit Care Med.* 2015; 192: 1020-1.
158. Sgalla G, Biffi A, **Richeldi L**. Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history. *Respirology* 2016; 21: 427-37.
159. **Richeldi L**. Textbook of Respiratory Medicine (Murray & Nadel's) - ELSEVIER Editor 2016 Italian edition
160. Britten N, Pope C, Halford S, **Richeldi L**. What if we made stratified medicine work for patients? *Lancet Respir Med.* 2016; 4: 8-10.
161. Cerri S, Sgalla G, **Richeldi L**, Luppi F. Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report. *J Med Case Rep.* 2016; 10: 127.
162. Sgalla G, Coconcelli E, Tonelli R, **Richeldi L**. Novel drug targets for idiopathic pulmonary fibrosis. *Expert Rev Respir Med.* 2016: 1-13.
163. Jones MG, Walsh SL, Jones KD, **Richeldi L**. Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient. *Eur Respir J.* 2016; 47: 1057-9.
164. Brownell R, Kaminski N, Woodruff PG, Bradford WZ, **Richeldi L**, Martinez FJ, Collard HR. Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med.* 2016; 193: 1213-8.
165. Kolb M, Jenkins G, **Richeldi L**. Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis. *Thorax.* 2016; 71: 399-400.
166. **Richeldi L**. How we will diagnose IPF in the future. *QJM.* 2016; 109: 581-3.
167. Fletcher S, Jones MG, Spinks K, Sgalla G, Marshall BG, Limbrey R, **Richeldi L**. The safety of new drug treatments for idiopathic pulmonary fibrosis. *Expert Opin Drug Saf.* 2016; 15: 1483-1489
168. Costabel U, Inoue Y, **Richeldi L**, Collard HR, Tschöepe I, Stowasser S, Azuma A. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. *Am J Respir Crit Care Med.* 2016; 193: 178-85.
169. Rochweg B, Neupane B, Zhang Y, Garcia CC, Raghu G, **Richeldi L**, Brozek J, Beyene J, Schünemann H. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. *BMC Med.* 2016; 14: 18.
170. **Richeldi L**, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. *Resp Med.* 2016; 113: 74-9.
171. Jones MG, Fabre A, Schneider P, Cinetto F, Sgalla G, Mavrogordato M, Jogai S, Alzetani A, Marshall BG, O'Reilly KMA, Warner JA, Lackie PM, Davies DE, Hansell DM, Nicholson

- AG, Sinclair I, Brown KK, **Richeldi L**. Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. *JCI Insight*. 2016; 1.
172. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, **Richeldi L**, Taniguchi H, Martinez FJ. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *Am J Respir Crit Care Med*. 2016; 194: 265-75.
173. Kolb M, **Richeldi L**, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. *Thorax*. 2016 Sep 26.
174. Raghu G, Wells AU, Nicholson AG, **Richeldi L**, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. *Am J Respir Crit Care Med*. 2017; 195: 78-85.
175. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, **Richeldi L**, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clin Infect Dis*. 2017; 64: 111-115.
176. Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B; **Richeldi L** HP Delphi Collaborators. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. *Am J Respir Crit Care Med*. 2017 Nov 27.
177. Nardini S, De Benedetto F, Sanguinetti CM, Bellofiore S, Carlone S, Privitera S, Saggiocca L, Tupputi E; with the collaboration of The Consensus Conference Group, Baccarani C, Caiffa G, Calabrese MC, Capuozzo A, Cauchi S, Conio V, Coratella G, Crismancich F, Dal Negro RW, Dellarole F, Delucchi M, Favaretti C, Forte S, Gallo FM, Giuliano R, Grandi M, Grillo A, Gualano MR, Guffanti E, Locicero S, Lombardo FP, Mantero M, Marasso R, Martino L, Mastroberardino M, Mereu C, Messina R, Neri M, Novelletto BF, Parente P, Pasquinucci S, Pistolesi M, Polverino M, Posca A, **Richeldi L**, Roccia F, Giustini ES, Salemi M, Santacroce S, Schisano M, Schisano M, Selvi E, Silenzi A, Soverina P, Taranto C, Ugolini M, Visaggi P, Zanasi A. COPD management as a model for all chronic respiratory conditions: report of the 4th Consensus Conference in Respiratory Medicine. *Multidiscip Respir Med*. 2017 Nov 10;12:28.
178. Martinez FJ, Collard HR, Pardo A, Raghu G, **Richeldi L**, Selman M, Swigris JJ, Taniguchi H, Wells AU. Idiopathic pulmonary fibrosis. *Nat Rev Dis Primers*. 2017 Oct 20;3:17074.
179. Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, **Richeldi L**, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. *BMJ Open Respir Res*. 2017 Sep 17;4(1):e000212.
180. Macagno F, Leone PM, **Richeldi L**. Managing patients with interstitial lung disease: Two more pieces of the puzzle. *Respirology*. 2017 Nov;22(8):1481-1482.
181. Inchingolo R, Condoluci C, Smargiassi A, Mastrobattista A, Boccabella C, Comes A, Golfi N, **Richeldi L**. Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? *Expert Opin Pharmacother*. 2017 Oct;18(15):1583-1594.

182. Sgalla G, **Richeldi L**. Using evidence in clinical practice: A dream coming true in idiopathic pulmonary fibrosis. *Rev Port Pneumol* (2006). 2017 Sep - Oct;23(5):245-246.
183. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, **Richeldi L**, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johansson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *Eur Respir J*. 2017 Aug 31;50(2).
184. Varone F, Montemurro G, Macagno F, Calvello M, Conte E, Intini E, Iovene B, Leone PM, Mari PV, **Richeldi L**. Investigational drugs for idiopathic pulmonary fibrosis. *Expert Opin Investig Drugs*. 2017 Sep;26(9):1019-1031.
185. Raghu G, **Richeldi L**. Current approaches to the management of idiopathic pulmonary fibrosis. *Respir Med*. 2017 Aug;129:24-30.
186. Aliberti S, Ramirez J, Giuliani F, Wiemken T, Sotgiu G, Tedeschi S, Carugati M, Valenti V, Marchioni M, Camera M, Piro R, Del Forno M, Milani G, Faverio P, **Richeldi L**, Deotto M, Villani M, Voza A, Tobaldini E, Bernardi M, Bellone A, Bassetti M, Blasi F. Individualizing duration of antibiotic therapy in community-acquired pneumonia. *Pulm Pharmacol Ther*. 2017 Aug;45:191-201.
187. Johansson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, **Richeldi L**, Wells AU, Vancheri C, Kreuter M; Erice ILD Working Group. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? *Lancet Respir Med*. 2017 Jul;5(7):591-598
188. Macagno F, Varone F, Leone PM, Mari PV, Panico L, Berardini L, **Richeldi L**. New treatment directions for IPF: current status of ongoing and upcoming clinical trials. *Expert Rev Respir Med*. 2017 Jul;11(7):533-548
189. Collard HR, **Richeldi L**, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R, Hallmann C, du Bois RM. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. *Eur Respir J*. 2017 May 19;49(5)
190. Magnini D, Montemurro G, Iovene B, Tagliaboschi L, Gerardi RE, Lo Greco E, Bruni T, Fabbrizzi A, Lombardi F, **Richeldi L**. Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies. *Respiration*. 2017;93(6):379-395.
191. Martinez FJ, Chisholm A, Collard HR, Flaherty KR, Myers J, Raghu G, Walsh SL, White ES, **Richeldi L**. The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. *Lancet Respir Med*. 2017;5:61-71.
192. Conforti F, Davies ER, Calderwood CJ, Thatcher TH, Jones MG, Smart DE, Mahajan S, Alzetani A, Havelock T, Maher TM, Molyneaux PL, Thorley AJ, Tetley TD, Warner JA, Packham G, Ganesan A, Skipp PJ, Marshall BJ, **Richeldi L**, Sime PJ, O'Reilly KMA, Davies DE. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. *Oncotarget*. 2017 Jul 25;8(30):48737-48754.
193. Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, **Richeldi L**. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. *JAMA*. 2018 Jun 12;319(22):2299-2307.
194. Sverzellati N, Odone A, Silva M, Polverosi R, Florio C, Cardinale L, Cortese G, Addonizio G, Zompatori M, Dalpiaz G, Piciucchi S, Larici AR, **Richeldi L** and other 37 collaborators;

- Italian Structured Report on Fibrosing Lung Disease Consort. *Radiol Med.* 2018 Apr;123(4):245-253.
195. Harold R. Collard, **Richeldi L** *Interstitial Lung Disease - ELSEVIER Editor* 2018.
 196. **Richeldi L**, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. *Thorax.* 2018 Jun;73(6):581-583.
 197. Flaherty KR, Kolb M, Vancheri C, Tang W, Conoscenti CS, **Richeldi L**. Stability or improvement in forced vital capacity with nintedanib in patients with IPF. *Eur Respir J.* 2018 Jun 25.
 198. Sgalla G, Walsh SLF, Sverzellati N, Fletcher S, Cerri S, Dimitrov B, Nikolic D, Barney A, Pancaldi F, Larcher L, Luppi F, Jones MG, Davies D, **Richeldi L**. "Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease. *BMC Pulm Med.* 2018 Jun 18;18(1):103.
 199. Bonniaud P, Fabre A, Frossard N, Guignabert C, Inman M, Kuebler WM, Maes T, Shi W, Stampfli M, Uhlig S, White E, Witzernrath M, Bellaye PS, Crestani B, Eickelberg O, Fehrenbach H, Guenther A, Jenkins G, Joos G, Magnan A, Maitre B, Maus UA, Reinhold P, Vernooij JHJ, **Richeldi L**, Kolb M. Optimising experimental research in respiratory diseases: an ERS statement. *Eur Respir J.* 2018 May 17;51(5).
 200. Sgalla G, Iovene B, Calvello M, Ori M, Varone F, **Richeldi L**. Idiopathic pulmonary fibrosis: pathogenesis and management. *Respir Res.* 2018 Feb 22;19(1):32.
 201. Kreuter M, Costabel U, **Richeldi L**, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S, Kolb M. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. *Respiration.* 2018;95(5):317-326
 202. Lynch DA, Sverzellati N, Travis WD, Colby TV, Inoue Y, Nicholson AG, Raouf S, **Richeldi L**, Ryerson CJ, Ryu JH. Diagnostic criteria for idiopathic pulmonary fibrosis - Authors' reply. *Lancet Respir Med.* 2018 Feb;6(2):e7.
 203. Castillo D, Walsh S, Hansell DM, Vasakova M, Cottin V, Altinisik G, Palmucci S, Sterclova M, Harari S, **Richeldi L**, Vancheri C, Wells AU; ERICE ILD working group. Validation of multidisciplinary diagnosis in IPF. *Lancet Respir Med.* 2018 Feb;6(2):88-89.
 204. Wolters PJ, Blackwell TS, Eickelberg O, Loyd JE, Kaminski N, Jenkins G, Maher TM, Molina-Molina M, Noble PW, Raghu G, **Richeldi L**, Schwarz MI, Selman M, Wuyts WA, Schwartz DA. Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic? *Lancet Respir Med.* 2018 Feb;6(2):154-160
 205. Varone F, Sgalla G, Iovene B, Bruni T, **Richeldi L**. Nintedanib for the treatment of idiopathic pulmonary fibrosis. *Expert Opin Pharmacother.* 2018 Feb;19(2):167-175.
 206. Vancheri C, Kreuter M, **Richeldi L**, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. *Am J Respir Crit Care Med.* 2018 Feb 1;197(3):356-363.
 207. Jones MG, Sgalla G, **Richeldi L**. Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med.* 2018 Jan 1;197(1):9-10.
 208. Kaner RJ, Bajwa EK, El-Amine M, Gorina E, Gupta R, Lazarus HM, Luckhardt TR, Mouded M, Posada K, **Richeldi L**, Stauffer J, Tutuncu A, Martinez FJ. Design of IPF Clinical Trials in the Era of Approved Therapies. *Am J Respir Crit Care Med.* 2019 Apr 15..

209. Kreuter M, Koegler H, Trampisch M, Geier S, **Richeldi L**. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials. *Respir Res*. 2019 Apr 11;20(1):71.
210. **Richeldi L**, Lauanders N, Martinez F, Walsh SLF, Myers J, Wang B, Jones M, Chisholm A, Flaherty KR. The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. *ERJ Open Res*. 2019 Apr 1;5(2).
211. Smargiassi A, Inchingolo R, Chiappetta M, Ciavarella LP, Lopatriello S, Corbo GM, Margaritora S, **Richeldi L**. Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: preliminary results. *Multidiscip Respir Med*. 2019 Mar 4;14:9.
212. Fuso L, Varone F, Magnini D, Calvello M, Lo Greco E, **Richeldi L**. New Frontiers in Ultrasonography of the Mediastinum: Pediatric EBUS-TBNA. *Respir Care*. 2019 Mar;64(3):358-359.
213. Inchingolo R, Pasciuto G, Magnini D, Cavalletti M, Scoppettuolo G, Montemurro G, Smargiassi A, Torelli R, Sanguinetti M, Spanu T, Corbo GM, **Richeldi L**. Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit. *BMC Infect Dis*. 2019 Mar 4;19(1):215.
214. Walsh SLF, **Richeldi L**. Subclinical Interstitial Lung Abnormalities; Lumping and Splitting Revisited. *Am J Respir Crit Care Med*. 2019 Jan 30.
215. Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, **Richeldi L**, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU. Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. *Respir Med*. 2019 Jan;146:42-48.
216. Sgalla G, Larici AR, Sverzellati N, Bartholmai B, Walsh SLF, Nikolic D, Barney A, Fletcher S, Jones M, Davies DD, **Richeldi L**. Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study. *Eur Respir J*. 2019 Mar 7;53(3).
217. **Richeldi L**, Fernández Pérez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet Respir Med*. 2019 Sep 27.
218. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, **Richeldi L**, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *N Engl J Med*. 2019 Oct 31;381(18):1718-1727.
219. Raghu G, Remy-Jardin M, Myers J, **Richeldi L**, Wilson KC. The 2018 Diagnosis of IPF Guidelines: Surgical Lung Biopsy in Probable UIP is Not Mandatory. *Am J Respir Crit Care Med*. 2019 Sep 9.
220. **Richeldi L**, Cottin V, Brown KK, Flaherty KR, Johannson KA, Travis WD, Collard HR. Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity. *Am J Respir Crit Care Med*. 2019 Oct 1;200(7):941-942.
221. **Richeldi L**, Crestani B, Azuma A, Kolb M, Selman M, Stansen W, Quaresma M, Stowasser S, Cottin V. Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. *Respir Med*. 2019 Sep; 156:20-25.
222. Hill C, Li J, Liu D, Conforti F, Breerton CJ, Yao L, Zhou Y, Alzetani A, Chee SJ, Marshall BG, Fletcher SV, Hancock D, Ottensmeier CH, Steele AJ, Downward J, **Richeldi L**, Lu X, Davies DE,

- Jones MG, Wang Y. Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. *Cell Death Dis.* 2019 Aug 7;10(8):591
223. Varone F, Gibiino G, Gasbarrini A, **Richeldi L.** Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy. *Eur Rev Med Pharmacol Sci.* 2019 Jul;23(14):6379-6386.
224. Walsh SLF, **Richeldi L.** Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey. *Eur Respir J.* 2019 Jul 25;54(1).
225. Mari PV, Lombardi F, Flore MC, **Richeldi L.** Statin Therapy and Lung Disorders. *Am J Respir Crit Care Med.* 2019 Oct 1;200(7):921-923.
226. Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, **Richeldi L,** Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU. Diagnostic Likelihood Thresholds that Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med.* 2019 Jun 26.
227. Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L, Quaresma M, Stowasser S, **Richeldi L.** Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. *BMJ Open Respir Res.* 2019 Mar 25;6(1):e000397.
228. **Richeldi L,** Cottin V, Würtemberger G, Kreuter M, Calvello M, Sgalla G. Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality? *Am J Respir Crit Care Med.* 2019 Jul 15;200(2):261-263.
229. **Richeldi L,** Sinclair I, Lackie PM, Schneider P. X-ray Micro-Computed Tomography for Nondestructive Three-Dimensional (3D) X-ray Histology. *Am J Pathol.* 2019 Aug;189(8):1608-1620.
230. Cottin V, Annesi-Maesano I, Günther A, Galvin L, Kreuter M, Powell P, Prasse A, Reynolds G, **Richeldi L,** Spagnolo P, Valenzuela C, Wijsenbeek M, Wuyts WA, Crestani B; Ariane-IPF Clinical Research Collaboration consortium. The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis. *Eur Respir J.* 2019 May 23;53(5).
231. Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder GJ, Gupta R, **Richeldi L.** Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. *Lancet Respir Med.* 2019 Aug;7(8):657-664.
232. Mari PV, G Jones M, **Richeldi L.** Contemporary Concise Review 2018: Interstitial lung disease. *Respirology.* 2019 Aug;24(8):809-816
233. Ryerson CJ, Kolb M, **Richeldi L,** Lee J, Wachtlin D, Stowasser S, Poletti V. Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. *ERJ Open Res.* 2019 Apr 29;5(2).
234. Sgalla G, Kulkarni T, Antin-Ozerkis D, Thannickal VJ, **Richeldi L.** Update in Pulmonary Fibrosis 2018. *Am J Respir Crit Care Med.* 2019 Aug 1;200(3):292-300.
235. Roman J, Barnes TR, Kervitsky DJ, Cosgrove GP, Doherty DE, Tager AM, **Richeldi L,** White ES, Brenner DA, Schnapp LM, Hewitson TD, Jugdutt BI, McKinsey TA, Tosi JD, Crane S, Brown KK; Fibrosis Across Organs Symposium Working Group. The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities. *Am J Med Sci.* 2019 May;357(5):405-410.
236. **Richeldi L,** Baldi F, Pasciuto G, Macagno F, Panico L. Current and Future Idiopathic Pulmonary Fibrosis Therapy. *Am J Med Sci.* 2019 May;357(5):370-373

237. Sgalla G, Larici AR, Re A, Farchione A, Cicchetti G, Calandriello L, Comes A, Golfi N, Iovene B, Varone F, Manfredi R, **Richeldi L**. Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study. *Eur Respir J*. 2019 Jun 27;53(6).
238. Kaner RJ, Bajwa EK, El-Amine M, Gorina E, Gupta R, Lazarus HM, Luckhardt TR, Mouded M, Posada K, **Richeldi L**, Stauffer J, Tutuncu A, Martinez FJ. Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. *Am J Respir Crit Care Med*. 2019 Jul 15;200(2):133-139.
239. Intini E, Kishore G, **Richeldi L**, Udawadia ZF. Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: what an Indian female patient tells us. *BMJ Case Rep*. 2019 Dec 4;12(12).
240. Bianco A, Mari PV, Larici AR, Lucchini M, Nociti V, Losavio FA, De Fino C, Cicchetti G, Coraci D, **Richeldi L**, Mirabella M. Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients. *Mult Scler Relat Disord*. 2019 Oct 15;37.
241. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, **Richeldi L**, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *N Engl J Med*. 2019 Oct 31;381(18):1718-1727.
242. Sgalla G, Flore M, Siciliano M, **Richeldi L**. Antibody-based therapies for idiopathic pulmonary fibrosis. *Expert Opin Biol Ther*. 2020 Jul;20(7):779-786.
243. **Richeldi L**, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, Quaresma M, Raghu G. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. *BMC Pulm Med*. 2020 Jan 8;20(1):3.
244. Varone F, Inoue Y, **Richeldi L**. Twenty-five years of Respiriology: Advances in idiopathic pulmonary fibrosis. *Respirology*. 2020 Jan;25(1):20-22.
245. **Richeldi L**, Fernández Pérez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet Respir Med*. 2020 Jan;8(1):25-33.
246. Bianco A, Mari PV, Larici AR, Lucchini M, Nociti V, Losavio FA, De Fino C, Cicchetti G, Coraci D, **Richeldi L**, Mirabella M. Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients. *Mult Scler Relat Disord*. 2020 Jan 37.
247. **Richeldi L**, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, Quaresma M, Raghu G. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. *BMC Pulm Med*. 2020 Jan 8;20(1):3.
248. Barnes H, Morisset J, Molyneaux P, Westall G, Glaspole I, Collard HR, **Richeldi L**; CHP Exposure Assessment Collaborators. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. *Chest*. 2020 Jan 17.
249. Sgalla G, Flore M, Siciliano M, **Richeldi L**. Antibody-based therapies for idiopathic pulmonary fibrosis. *Expert Opin Biol Ther*. 2020 Mar 2:1-8.
250. Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, **Richeldi L**, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Respir Med*. 2020 May;8(5):453-460.
251. Leone PM, **Richeldi L**. Current Diagnosis and Management of Hypersensitivity Pneumonitis. *Tuberc Respir Dis (Seoul)*. 2020 Apr;83(2):122-131.

252. Sgalla G, Lo Greco E, Calvello M, Varone F, Iovene B, Cerri S, Donatelli P, Vancheri A, Pavone M, Luppi F, Vancheri C, **Richeldi L**. Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. *Respirology*. 2020 Mar 19.
253. Niederman MS, **Richeldi L**, Chotirmall SH, Bai C. Rising to the Challenge of the Novel SARS-coronavirus-2 (SARS-CoV-2): Advice for Pulmonary and Critical Care and an Agenda for Research. *Am J Respir Crit Care Med*. 2020 May 1;201(9):1019-1022.
254. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raof S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, Inoue Y, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, **Richeldi L**, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Radiology*. 2020 Jul;296(1):172-180.
255. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raof S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, Inoue Y, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, **Richeldi L**, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Chest*. 2020 Jul;158(1):106-116.
256. Sgalla G, **Richeldi L**. Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone? *J Bras Pneumol*. 2020;46(2):e20200193.
257. Jones MG, Hillyar CRT, Nibber A, Chisholm A, Wilson A, Maher TM, Kaplan A, Price D, Walsh S, **Richeldi L**; RESPIRATORY EFFECTIVENESS GROUP'S INTERSTITIAL LUNG DISEASE WORKING GROUP. Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study. *Respirology*. 2020 May 11.
258. Bassetti M, Giacobbe DR, Aliberti S, Barisione E, Centanni S, De Rosa FG, Di Marco F, Gori A, Granata G, Mikulska M, Petrosillo N, **Richeldi L**, Santus P, Tascini C, Vena A, Viale P, Blasi F; Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of anti-infective therapy (SITA) and the Italian Society of Pulmonology (SIP). *Clin Microbiol Infect* 2020 Jul;26(7):880-894
259. Marra R, Sgalla G, **Richeldi L**, Conte EG, Hill AT. Role of *Stenotrophomonas maltophilia* isolation in patients with non CF bronchiectasis. *QJM* 2020 Apr 10.
260. Varone F, Iovene B, Sgalla G, Calvello M, Calabrese A, Larici AR, **Richeldi L**. Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management. *Lung*. 2020 Jun;198(3):429-440.
261. Hatabu H, Hunninghake GM, **Richeldi L**, Brown KK, Wells AU, Remy-Jardin M, Verschakelen J, Nicholson AG, Beasley MB, Christiani DC, San José Estépar R, Seo JB, Johkoh T, Sverzellati N, Ryerson CJ, Graham Barr R, Goo JM, Austin JHM, Powell CA, Lee KS, Inoue Y, Lynch DA. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. *Lancet Respir Med* 2020 Jul;8(7):726-737.
262. Smargiassi A, Soldati G, Borghetti A, Scoppettuolo G, Tamburrini E, Testa AC, Moro F, Natale L, Larici AR, Buonsenso D, Valentini P, Draisci G, Zanfini BA, Pompili M, Scambia G, Lanzone A, Franceschi F, Rapaccini GL, Gasbarrini A, Giorgini P, **Richeldi L**, Demi L, Inchingolo R. Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic. *J Ultrasound* 2020 Jul 7;1-8.
263. George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, **Richeldi L**, Tomassetti S, Valenzuela C, Vancheri C, Varone F, Cottin V, Costabel U; Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. *Lancet Respir Med* 2020 Sep;8(9):925-934.

264. Bellieni A, Intini E, Taddei E, Baldi F, Larosa L, Murri R, **Richeldi L**, Bernabei R, Cauda R, Landi F, Corbo GM, Fantoni M. Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? *Infect Dis (Lond)* 2020 Aug;52(8):585-589.
265. Sgalla G, Franciosa C, Simonetti J, **Richeldi L**. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. *Expert Opin Investig Drugs* 2020 Jun 7;1-7.
266. Papi A, Blasi F, Canonica GW, Morandi L, **Richeldi L**, Rossi A. Treatment strategies for asthma: reshaping the concept of asthma management. *Allergy Asthma Clin Immunol* 2020 Aug 15;16:75.
267. Bruni T, Lalvani A, **Richeldi L**. Telemedicine-enabled Accelerated Discharge of Patients Hospitalized with COVID-19 to Isolation in Repurposed Hotel Rooms. *Am J Respir Crit Care Med* 2020 Aug 15;202(4):508-510.
268. Comes A, Sgalla G, **Richeldi L**. Early diagnosis of idiopathic pulmonary fibrosis: Closer to the goal? *Eur J Intern Med.* 2020 Oct;80:12-13.
269. Varone F, Friello L, Di Blasi C, Sgalla G, Luigetti M, Iovene B, **Richeldi L**, Della Marca G, Brunetti V. Restless legs syndrome: A new comorbidity in idiopathic pulmonary fibrosis. *Respir Med* Aug-Sep 2020;170:105982.
270. Cocconcelli E, Tonelli R, Abbati G, Marchioni A, Castaniere I, Pelizzaro F, Russo FP, Vegetti A, Balestro E, Pietrangelo A, **Richeldi L**, Luppi F, Spagnolo P, Clini E, Cerri S. Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis. *Intern Emerg Med* 2020 May 25.
271. Conforti F, Ridley R, Brereton C, Alzetani A, Johnson B, Marshall BG, Fletcher SV, Ottensmeier CH, **Richeldi L**, Skipp P, Wang Y, Jones MG, Davies DE. Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. *Cell Death Discov* 2020 Jun 30;6:54.
272. Azuma A, **Richeldi L**. New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases. *Tuberc Respir Dis (Seoul)* 2020 Jul;83(3):195-200.
273. Brereton CJ, Wallis T, Casey M, Fox L, Pontopiddan K, Laws D, Graves J, Titmuss V, Kearney S, Evans S, Grove A, Hamid S, **Richeldi L**, O'Reilly KMA, Fletcher SV, Jones MG. Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes? *ERJ Open Res.* 2020 Jul 20;6(2):00120-2020.
274. **Richeldi L**, Scholand MB, Lynch DA, Colby TV, Myers JL, Groshong SD, Chung JH, Benzaquen S, Nathan SD, Davis JR, Schmidt SL, Hagemeyer L, Sonetti D, Hetzel J, Criner GJ, Case AH, Ramaswamy M, Calero K, Gauhar UA, Patel NM, Lancaster L, Choi Y, Pankratz DG, Walsh PS, Lofaro LR, Huang J, Bhorade SM, Kennedy GC, Martinez FJ, Raghu G. Utility of a Molecular Classifier as a Complement to HRCT to Identify Usual Interstitial Pneumonia. *Am J Respir Crit Care Med.* 2020 Jul 28.
275. Sgalla G, Larici AR, Golfi N, Calvello M, Farchione A, Del Ciello A, Varone F, Iovene B, Manfredi R, **Richeldi L**. Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends. *BMC Pulm Med.* 2020 Sep 21;20(1):249.
276. Gemelli Against COVID-19 Post-Acute Care Study Group (Richeldi L). Post-COVID-19 global health strategies: the need for an interdisciplinary approach. *Aging Clin Exp Res.* 2020 Aug;32(8):1613-1620.
277. Luigetti M, Iorio R, Bentivoglio AR, Tricoli L, Riso V, Marotta J, Piano C, Primiano G, Zileri Dal Verme L, Lo Monaco MR, Calabresi P; GEMELLI AGAINST COVID-19 group (**Richeldi L**). Assessment of neurological manifestations in hospitalized patients with COVID-19. *Eur J Neurol.* 2020 Jul 18.
278. Ianiro G, Porcari S, Settanni CR, Bibbò S, Ponziani FR, Zileri Dal Verme L, Franceschi F, Cammarota G, Gasbarrini A; Gemelli against COVID-19 Working Group (**Richeldi L**). Letter:

- prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. *Aliment Pharmacol Ther.* 2020 Sep;52(5):902-903.
279. De Lorenzis E, Bosello SL, Varone F, Sgalla G, Calandriello L, Natalello G, Iovene B, Cicchetti G, Gigante L, Verardi L, Gremese E, **Richeldi L**, Larici AR. Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement. *Diagnostics (Basel)* 2020 Sep 2;10(9):E664.
280. Lasky JA, Criner GJ, Lazarus HM, Kohlbrenner V, Bender S, **Richeldi L**. Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data. *Adv Ther.* 2020 Oct;37(10):4209-4219.
281. Varone F, Sgalla G, Iovene B, **Richeldi L**. Progressive Fibrosing Interstitial Lung Disease: A Proposed Integrated Algorithm for Management. *Ann Am Thorac Soc.* 2020 Jul 1.
282. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. Olson A, Hartmann N, Patnaik P, Wallace L, Schlenker-Herceg R, Nasser M, **Richeldi L**, Hoffmann-Vold AM, Cottin V. *Adv Ther.* 2021 Feb;38(2):854-867.
283. Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. **Richeldi L**, Scholand MB, Lynch DA, Colby TV, Myers JL, Groshong SD, Chung JH, Benzaquen S, Nathan SD, Davis JR, Schmidt SL, Hagemeyer L, Sonetti D, Hetzel J, Criner GJ, Case AH, Ramaswamy M, Calero K, Gauhar UA, Patel NM, Lancaster L, Choi Y, Pankratz DG, Walsh PS, Lofaro LR, Huang J, Bhorade SM, Kennedy GC, Martinez FJ, Raghu G. *Am J Respir Crit Care Med.* 2021 Jan 15;203(2):211-220.
284. Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, **Richeldi L**, Schaefer-Prokop CM, Verschakelen J, Raof S, Rubin GD, Powell C, Inoue Y, Hatabu H. *Radiology.* 2021 Mar;298(3):550-566.
285. The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol. **Richeldi L**, Piraino A, Macagno F, Micarelli G, Ingrassia E. *Int J Chron Obstruct Pulmon Dis.* 2021 Jan 27;16:159-166.
286. Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, **Richeldi L**, Schaefer-Prokop CM, Verschakelen J, Raof S, Rubin GD, Powell C, Inoue Y, Hatabu H. *Chest.* 2021 Jan 12:S0012-3692(20)35313-7.
287. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. Bagnasco D, Povero M, Pradelli L, Brussino L, Rolla G, Caminati M, Menzella F, Heffler E, Canonica GW, Paggiaro P, Senna G, Milanese M, Lombardi C, Bucca C, Manfredi A, Canevari RF, Passalacqua G, **Richeldi L** SANI Network (Severe Asthma Network Italy). *World Allergy Organ J.* 2021 Jan 27;14(2):100509.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e del Regolamento UE 2016/679.e ss.mm.i.

05.03.2021

Prof. Luca Richeldi

A handwritten signature in black ink, appearing to read "Luca Richeldi", written over the printed name.